Bristol Myers Squibb (BMY) ended the recent trading session at $56.81, demonstrating a -0.58% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.16%.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

The stock's fall snapped a two-day winning streak.

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with ...

Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...